Enhanced Postsurgical Cancer Treatment Using Methacrylated Glycol Chitosan Hydrogel for Sustained DNA/Doxorubicin Delivery and Immunotherapy

  • Biomater Res. 2024 Mar 23:28:0008. doi: 10.34133/bmr.0008.
Hee Seung Seo  1  2 ,  Jun-Hyeok Han  2  3 ,  Jaesung Lim  1  2 ,  Ga-Hyun Bae  3  4 ,  Min Ji Byun  1  2 ,  Chi-Pin James Wang  1  2 ,  Jieun Han  3  5 ,  Juwon Park  6 ,  Hee Ho Park  7 ,  Mikyung Shin  1  2 ,  Tae-Eun Park  8 ,  Tae-Hyung Kim  9 ,  Se-Na Kim  10 ,  Wooram Park  3  4  5  11 ,  Chun Gwon Park  1  2  12
Affiliations
  • 1. Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea.
  • 2. Department of Intelligent Precision Healthcare Convergence, Institute for Convergence, SKKU, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea.
  • 3. Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, SKKU, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea.
  • 4. Department of MetaBioHealth, SKKU Institute for Convergence, SKKU, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea.
  • 5. Institute of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, SKKU, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea.
  • 6. Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA.
  • 7. Department of Bioengineering, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea.
  • 8. Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, 50, UNIST-gil, Ulsan 44919, Republic of Korea.
  • 9. School of Integrative Engineering, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea.
  • 10. Research and Development Center, MediArk Inc., 1, Chungdae-ro, Seowon-gu, Cheongju, Chungcheongbuk 28644, Republic of Korea.
  • 11. Biomaterials Research Center, Korea Institute of Science and Technology, 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
  • 12. Biomedical Institute for Convergence, SKKU, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea.
PMID: 38532906 DOI: 10.34133/bmr.0008
Abstract

Background: Cancer recurrence and metastasis are major contributors to treatment failure following tumor resection surgery. We developed a novel implantable drug delivery system utilizing glycol chitosan to address these issues. Glycol chitosan is a natural Adjuvant, inducing dendritic cell activation to promote T helper 1 cell immune responses, macrophage activation, and cytokine production. Effective antigen production by dendritic cells initiates T-cell-mediated immune responses, aiding tumor growth control. Methods: In this study, we fabricated multifunctional methacrylated glycol chitosan (MGC) hydrogels with extended release of DNA/doxorubicin (DOX) complex for Cancer Immunotherapy. We constructed the resection model of breast Cancer to verify the Anticancer effects of MGC hydrogel with DNA/DOX complex. Results: This study demonstrated the potential of MGC hydrogel with extended release of DNA/DOX complex for local and efficient Cancer therapy. The MGC hydrogel was implanted directly into the surgical site after tumor resection, activating tumor-related immune cells both locally and over a prolonged period of time through immune-reactive molecules. Conclusions: The MGC hydrogel effectively suppressed tumor recurrence and metastasis while enhancing immunotherapeutic efficacy and minimizing side effects. This biomaterial-based drug delivery system, combined with Cancer Immunotherapy, can substantial improve treatment outcomes and patient prognosis.

Products